Gilead’s HIV treatment demonstrates high efficacy and viral suppression at five years
pharmafile | February 14, 2022 | News story | Sales and Marketing |
Gilead Sciences has announced the presentation of cumulative five-year results from two Phase III studies of Biktarvy. The new, long-term data further show the sustained efficacy and safety profile, as well as lack of treatment failure due to resistance in the final resistance analysis population associated with Biktarvy, for the treatment of HIV in adults.
Through the five years of analysis, zero cases of treatment failure due to emergent resistance were detected among the final resistance analysis population of both studies.
Biktarvy is a complete HIV-1 treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available. It offers simple once-daily dosing with or without food.
“These latest data presented at CROI help us better understand the role of Biktarvy for long-term treatment and demonstrate its long-term viral suppression and durability,” said David Alain Wohl, MD, Professor of Medicine, Division of Infectious Diseases, the University of North Carolina at Chapel Hill. “Many people living with HIV are concerned about the ability of their therapy to achieve long-term viral suppression since they will likely be on treatment for the duration of their lives. Confidence in the efficacy and robustness of Biktarvy as a complete regimen helps me advance the conversation around what long-term treatment success may look like.”
“Effective treatment options, such as Biktarvy, are an important tool in addressing the specific needs of certain people living with HIV, including achieving and maintaining an undetectable viral load over the long-term,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences.
“As we strive to improve HIV treatment and continue to advance scientific innovation, we’re committed to looking beyond viral load suppression to gain a better understanding of how to support the long-term and overall health of people living with HIV. The five-year data presented at CROI are an important step in deepening our understanding of how to tailor our research program to address the individual needs of all people living with HIV, and to help end the global HIV epidemic.”
Lina Adams
